Literature DB >> 18560410

Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT.

D K L Cheuk1, A S P Mok, A C W Lee, A K S Chiang, S Y Ha, Y L Lau, G C F Chan.   

Abstract

In this cross-sectional study, we compared the quality of life (QOL) in transfusion-dependent thalassemic patients who survived matched sibling hematopoietic SCT (HSCT, n=24) with patients treated conventionally with transfusion and iron chelation (n=74). WHOQOL-BREF(HK) and PedsQL questionnaires were administered to patients aged >18 years and 5-12 years, respectively. Patients aged 12-18 years received both questionnaires. WHOQOL-BREF(HK) revealed post transplant patients rated overall health better than those treated conventionally (score 3.67 vs 3.06, P=0.01). They are less dependent on medical aids (3.87 vs 2.96, P=0.006), having higher activity level (4.00 vs 3.36, P=0.026) and better personal relationships (4.13 vs 3.69, P=0.014). Physical health domain score was better (75.20 vs 63.94, P=0.007). These differences remained significant after adjustment for comorbidities. PedsQL revealed post transplant patients rated better for running (3.53 vs 2.72, P=0.001) and sports (3.20 vs 2.64, P=0.038), even after adjustment for comorbidities, but were less satisfied for school absence to attend hospital (2.53 vs 3.29, P=0.03). Post transplant patients were significantly more likely to consider marriage (100 vs 75.7%, P=0.033), but not childbearing (66.7 vs 51.4%, P=0.28). In conclusion, transplanted thalassemic patients enjoy better QOL, mainly in physical health, compared with conventionally treated patients. This information is important to patients considering HSCT.

Entities:  

Mesh:

Year:  2008        PMID: 18560410     DOI: 10.1038/bmt.2008.165

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  17 in total

1.  Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT).

Authors:  Michael J Kelly; Brian W Pennarola; Angie Mae Rodday; Susan K Parsons
Journal:  Pediatr Blood Cancer       Date:  2011-12-19       Impact factor: 3.167

2.  Second bone marrow transplantation for patients with thalassemia: risks and benefits.

Authors:  Polina Stepensky; Reuven Or; Michael Y Shapira; Shoshana Revel-Vilk; Jerry Stein; Igor B Resnick
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

Review 3.  Quality of Life in Thalassemia Major.

Authors:  V P Choudhry
Journal:  Indian J Pediatr       Date:  2018-09-21       Impact factor: 1.967

4.  Return to normal life after hematopoietic stem cell transplantation for thalassemia: a study of patients transplanted from matched sibling donors.

Authors:  G Caocci; A Vacca; E Piras; V Serreli; C Dessi; M Marcias; P Risso; G La Nasa
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

5.  A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy.

Authors:  Sherif M Badawy; Usman Beg; Robert I Liem; Sonali Chaudhury; Alexis A Thompson
Journal:  Blood Adv       Date:  2021-01-26

6.  Quality of Life (QoL) and the Factors Affecting it in Transfusion-dependent Thalassemic Children.

Authors:  Kapil Chordiya; Vikash Katewa; Pramod Sharma; Bindu Deopa; Suman Katewa
Journal:  Indian J Pediatr       Date:  2018-05-12       Impact factor: 1.967

7.  A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.

Authors:  Pattara Leelahavarong; Usa Chaikledkaew; Suradej Hongeng; Vijj Kasemsup; Yoel Lubell; Yot Teerawattananon
Journal:  BMC Health Serv Res       Date:  2010-07-16       Impact factor: 2.655

8.  Health-related quality of life in pediatric patients after allogeneic SCT: development of the PedsQL Stem Cell Transplant module and results of a pilot study.

Authors:  A Lawitschka; E D Güclü; J W Varni; M Putz; D Wolff; S Pavletic; H Greinix; C Peters; R Felder-Puig
Journal:  Bone Marrow Transplant       Date:  2014-05-12       Impact factor: 5.483

9.  Comparison of Blood Transfusion Plus Chelation Therapy and Bone Marrow Transplantation in Patients with β-Thalassemia: Application of SF-36, EQ-5D, and Visual Analogue Scale Measures.

Authors:  Mehdi Javanbakht; Ali Keshtkaran; Hossien Shabaninejad; Hassan Karami; Maryam Zakerinia; Sajad Delavari
Journal:  Int J Health Policy Manag       Date:  2015-06-13

10.  Hematopoietic stem cell transplantation for people with β-thalassaemia.

Authors:  Akshay Sharma; Vanitha A Jagannath; Latika Puri
Journal:  Cochrane Database Syst Rev       Date:  2021-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.